While the expression of AGR3 in the serous type of ovarian cancer predicts prolonged patient survival [127], AGR3 expression in colorectal cancer (CRC) predicts poor survival [124], which may be attributed to the ability of AGR3 to promote Wnt/β-catenin signaling and stemness in CRC cells [124]. This evidence concerns the gene AGR3 and ovarian carcinoma.